



Syncom Formulations (India) Limited

A WHO-GMP & ISO 9001-2000 Certified Company

CIN No.: L24239MH1988PLC047759

SYNCOM/SE/2024-25

11th November, 2024

Online filing at: www.listing.bseindia.com and
<https://neaps.nseindia.com/NEWLISTINGCORP/login.jsp>

To,
BSE Limited
Phiroze Jeejeebhoy Tower,
Dalal Street,
Mumbai (M.H.) 400 001
BSE CODE:524470

To,
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex, Bandra (E),
Mumbai- 400051
NSE SYMBOL: SYNCOMF

Subject: Regulation 33(3) of SEBI (LODR) Regulations, 2015 - Submission of Standalone & Consolidated unaudited Financial Results along with Limited Review Report, Statement of Assets and Liabilities and Cash Flow for the quarter and half year ended on 30th September, 2024.

Dear Sir/Ma'am

This is in continuation of our letter no. **SYNCOM/SE/2024-25** dated 4th November, 2024 regarding intimation of Board meeting for consideration and approval of Standalone and Consolidated Un-Audited Financial Results for the Quarter/ Half Year ended 30th September, 2024.

Pursuant to Regulation 33(3) of SEBI (LODR) Regulations, 2015, we are pleased to submit the following:

1. Standalone and Consolidated Un-Audited Financial Results of the Company for the Quarter/ Half Year ended on 30th September, 2024;
2. Standalone and Consolidated Limited Review Report by the Statutory Auditors of the company for the Quarter/ Half Year ended on 30th September, 2024;
3. Standalone and Consolidated Un-Audited Statement of Assets and Liabilities for the Half Year ended on 30th September, 2024; and
4. Standalone and Consolidated Un-Audited Statement of Cash Flow for the Half year ended on 30th September, 2024.

which was considered and approved by the Board at their Meeting held on Monday, the 11th November, 2024 at 4:00 P.M. and **Concluded at 5:15 P.M.**

We are also in process to file the aforesaid financial results in XBRL format within the stipulated time and the same shall also be hosted on the website of the company.

The Financial Results will also be published in widely circulated English and Marathi (Vernacular) newspaper in the prescribed format within the stipulated time period.

The Board Meeting commenced at 4:00 P.M. and **Concluded at 5:15 P.M.**

You are requested to take on record the unaudited Financial Results, Statement of Assets and Liabilities and Cash Flow along with Limited Review Report for your reference and record.

Thanking You,
Yours Faithfully,

For, SYNCOM FORMULATIONS (INDIA) LIMITED

**CS VAISHALI AGRAWAL
COMPANY SECRETARY &
COMPLIANCE OFFICER**

Encl: a/a

Bringing a smile on every face...

Regd. Off. : 7, Niraj Industrial Estate, Off Mahakali Caves Road, Andheri (East), MUMBAI-400 093, INDIA, Tel.: 91-022-30887744-54, Fax: 91-022-30887755, Email: sfil87@syncomformulations.com

Works : 256-257, Sector-I, PITHAMPUR, Dist.-Dhar, M.P. - 454 775, INDIA, Tel.: 91-07292-403122, 407039, Fax: 91-07292-253404, Email: assistant2@sfil.in

Corp. Off. : 207, Saket Nagar, Near Saket Club, INDORE - 452 018, INDIA. Tel. : 91-0731-2700458, Email : finance@sfil.in

Website : <http://www.sfil.in>



SYNCOM FORMULATIONS (INDIA) LIMITED

Regd.Off :- 7,Niraj Industrial Estate,Off Mahakali Caves Road,Andheri (E) Mumbai-400093

Works:- 256-257, Sector - 1, Pithampur, Dist: Dhar-454775

E Mail:- finance@sfl.in, Website:- www.sfl.in, CIN :- L24239MH1988PLC047759

STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 30TH SEPTEMBER, 2024

(Rs.In Lakhs) (Except EPS)

S. No.	Particulars	Quarter Ended			Year to date Ended		Year Ended
		30-09-2024	30-06-2024	30-09-2023	30-09-2024	30-09-2023	31-03-2024
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Revenue from Operations	10149.25	8586.43	6238.68	18735.68	12175.11	25835.96
2	Other Income	418.35	227.97	400.35	646.32	588.09	1310.06
3	Total Income (1 + 2)	10567.60	8814.40	6639.03	19382.00	12763.20	27146.02
4	EXPENSES						
	(a) Cost of materials consumed	6857.57	5303.13	3325.08	12160.70	5590.39	13152.91
	(b) Purchases of Stock-in-Trade	1260.24	406.08	819.89	1666.32	1733.97	2620.83
	(c) Changes in inventories of finished goods, Stock-in- Trade and work-in-progress	(1560.83)	(263.29)	(308.60)	(1824.12)	81.93	(218.10)
	(d) Employee benefits expense	1240.39	1084.76	900.10	2325.15	1662.91	3505.77
	(e) Finance costs	16.22	38.65	107.57	54.87	219.74	444.87
	(f) Depreciation and amortization expense	130.00	130.00	87.88	260.00	197.88	472.23
	(g) Other expenses	1158.89	1105.38	893.03	2264.27	1890.96	3993.12
	Total expenses (4)	9102.48	7804.71	5824.95	16907.19	11367.78	23967.63
5	Profit/(loss) before exceptional items and tax (3- 4)	1465.12	1009.69	814.08	2474.81	1395.42	3178.39
6	Exceptional Items	(0.24)	0.00	0.00	(0.24)	0.00	(2.39)
7	Profit/(loss) before tax (5 - 6)	1464.88	1009.69	814.08	2474.57	1395.42	3176.00
8	Tax expense:						
	(1) Current tax	348.55	243.77	148.41	592.32	308.71	758.25
	(2) Deferred tax	21.33	3.06	45.12	24.39	41.31	55.43
9	Profit (Loss) for the period from continuing operations (7- 8)	1095.00	762.86	620.55	1857.86	1045.40	2362.32
10	Profit/(loss) from discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
11	Tax expense of discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
12	Profit/(loss) from Discontinued operations (after tax) (10-11)	0.00	0.00	0.00	0.00	0.00	0.00
13	Profit/(loss) for the period (9 + 12)	1095.00	762.86	620.55	1857.86	1045.40	2362.32
14	Other Comprehensive Income						
	A(i) Items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
	(ii) Income tax relating to items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
	B (i) Items that will be reclassified to profit or loss	391.88	275.93	124.34	667.81	331.11	681.39
	(ii) Income tax relating to items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
15	Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit (Loss) and Other Comprehensive Income for the period)	1486.88	1038.79	744.89	2525.67	1376.51	3043.71
16	Paid up Share Capital of the Company (Face Value 1/-)	9400.00	9400.00	9400.00	9400.00	9400.00	9400.00
17	Reserves excluding revaluation reserves	-	-	-	-	-	19245.18
18	Earnings per equity share (for continuing operation):						
	(1) Basic	0.16	0.11	0.08	0.27	0.15	0.32
	(2) Diluted	0.16	0.11	0.08	0.27	0.15	0.32
19	Earnings per equity share (for discontinued operation):						
	(1) Basic	0.00	0.00	0.00	0.00	0.00	0.00
	(2) Diluted	0.00	0.00	0.00	0.00	0.00	0.00
20	Earnings per equity share (for discontinued & continuing operations)						
	(1) Basic	0.16	0.11	0.08	0.27	0.15	0.32
	(2) Diluted	0.16	0.11	0.08	0.27	0.15	0.32

Place: Indore
Date: 11-11-2024

For, Syncom Formulations (India) Limited

Kedarmal Shankarlal Bankda
Chairman & Wholetime Director
DIN: 00023050



SYNCOM FORMULATIONS (INDIA) LIMITED

Regd.Off :- 7,Niraj Industrial Estate,Off Mahakali Caves Road,Andheri (E) Mumbai-400093

Works - 256-257, Sector - 1, Pithampur, Dist: Dhar-454775

E Mail - finance@sfil.in, Website:- www.sfil.in, CIN :- L24239MH1988PLC047759

STANDALONE STATEMENT OF SEGMENT WISE REVENUE, RESULTS ALONG WITH QUARTERLY AND YEARLY UNAUDITED RESULTS

(Rs.in Lakhs) (Except EPS)

S. No.	Particulars	Quarter Ended			Year to date Ended		Previous Year Ended
		30-09-2024	30-06-2024	30-09-2023	30-09-2024	30-09-2023	31-03-2024
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Segment Revenue						
	a) Pharmaceuticals Drugs & Formulations	10218.43	8585.33	6255.88	18803.76	11815.29	25,672.79
	b) Trading of Commodities	251.10	132.41	286.04	383.51	743.02	1,071.34
	c) Renting of Property	98.07	96.66	97.11	194.73	204.89	401.89
	Total Segment Revenue	10567.60	8814.40	6639.03	19382.00	12763.20	27,146.02
	Less: Inter Segment Revenue	0.00	0.00	0.00	0.00	0.00	0.00
	Revenue from Operations	10567.60	8814.40	6639.03	19382.00	12763.20	27,146.02
2	Segment Results Profit(+)/Loss(-) before tax and interest from each segment						
	a) Pharmaceuticals Drugs & Formulations	1382.69	955.36	823.70	2338.05	1419.68	3,232.76
	b) Trading of Commodities	8.40	4.39	5.38	12.79	-0.32	18.49
	c) Renting of Property	90.01	88.59	92.57	178.60	195.80	369.62
	Total Profit before tax	1481.10	1048.34	921.65	2529.44	1615.16	3,620.87
	Less: i) Interest	16.22	38.65	107.57	54.87	219.74	444.87
	ii) Other Un-allocable Expenditure	0.00	0.00	0.00	0.00	0.00	0.00
	Profit before tax	1464.88	1009.69	814.08	2474.57	1395.42	3,176.00
3	(Segment Asset-Segment Liabilities)						
	Segment Asset						
	a) Pharmaceuticals Drugs & Formulations	31234.08	29437.25	34624.25	31234.08	34624.25	33,390.18
	b) Trading of Commodities	971.86	964.42	1063.79	971.86	1063.79	1,026.45
	c) Renting of Property	4733.45	4733.45	4733.45	4733.45	4733.45	4,733.45
	Total Segment Asset	36939.39	35135.12	40421.49	36939.39	40421.49	39,150.08
	Un-allocable Assets	0.00	0.00	0.00	0.00	0.00	0.00
	Net Segment Asset	36939.39	35135.12	40421.49	36939.39	40421.49	39,150.08
	Segment Liabilities						
	a) Pharmaceuticals Drugs & Formulations	5432.16	5050.13	13155.03	5432.16	13155.03	10,181.37
	b) Trading of Commodities	243.87	167.45	131.38	243.87	131.38	151.93
	c) Renting of Property	92.52	181.32	163.44	92.52	163.44	171.60
	Total Segment Liabilities	5768.55	5398.90	13449.85	5768.55	13449.85	10,504.90
	Un-allocable Liabilities	0.00	0.00	0.00	0.00	0.00	-
	Net Segment Liabilities	5768.55	5398.90	13449.85	5768.55	13449.85	10,504.90

Notes:-

1 The above results were reviewed by the Audit Committee and approved by the Board at its meeting held on 11/11/2024.

These above results have been prepared in compliance with the Indian Accounting Standard (referred to as "Ind AS") as notified prescribed under Section 133 of the Companies Act, 2013 read with Companies (Indian Accounting Standards) Rules 2015 as amended from time to time.

2 The company is operating in 3 segments i.e. (a) Pharmaceuticals Drugs & Formulations (b) Trading of Commodities (c) Renting of Property, particulars of segment wise results are given as required.

3 The Standalone Statement of Assets and Liabilities as at 30th September, 2024 and the Standalone Statement of Cash Flow is provided as an annexure to this statement.

4

As required under Regulation 33 of SEBI (LODR) Regulations, 2015 the limited review by the Statutory Auditors have been completed for the quarter ended on 30th September 2024. The report does not have any impact on the above results and notes which needs explanation.

5 Previous period figures have been regrouped/reclassified wherever necessary to confirm to this period classification.

Place: Indore

Date: 11/11/2024

For, Syncom Formulations (India) Limited

Kedarnal Shankarlal Bankda
Chairman & Wholtime Director

DIN: 00023050

SYNCOM FORMULATIONS (INDIA) LIMITED

Regd. Off - 7, Niraj Industrial Estate, Off Mahakali Caves Road, Andheri (E) Mumbai-400093

Works - 250-257, Sector - 1, Pithampur, Dist. Dhar-454775

E Mail - finance@sfil.in, Website - www.sfil.in, CIN - L24239MH1988PLC047759

Standalone Statement of Assets & Liabilities as at 30/09/2024



Particulars	30-09-2024 unaudited	31-03-2024 Audited
Rs. in Lacs		
ASSETS		
Non-current assets		
(a) Property, Plant and Equipment	6,999.22	7,230.60
(b) Capital Work in Progress	142.11	-
(c) Intangible assets	4.72	11.05
(d) Investment Property	4,733.44	4,733.44
(e) Financial Assets	-	
(i) Investments	558.69	251.92
(ii) Fixed Deposits & Accrued Interest	15.77	586.64
(iii) Deposits	56.85	51.90
(f) Other Non Current Assets	49.56	20.56
Current assets		
(a) Inventories	4,505.31	2,108.15
(b) Financial Assets	-	
(i) Investments	8,012.38	6,369.94
(ii) Trade Receivables	8,662.76	9,321.46
(iii) Cash And Cash Equivalents	21.73	6,335.05
(iv) Bank Balances other than (iii) above	1,163.16	448.21
(v) Deposits	340.14	412.00
(vi) Loans & Advances	542.59	429.33
(d) Other Current Assets	1,130.96	839.83
Total	36,939.39	39,150.08
EQUITY AND LIABILITIES		
Equity		
(a) Equity Share Capital	9,400.00	9,400.00
(b) Other Equity	21,770.84	19,245.18
Liabilities		
Non Current Liabilities		
(a) Financial Liabilities	-	
(i) Trade and other Deposits	92.52	171.60
(b) Provisions	370.44	330.38
(c) Deferred Tax Liabilities (Net)	522.06	497.67
Current liabilities		
(a) Financial liabilities	-	
(i) Borrowings	1,367.21	7,165.03
(ii) Trade Payables	-	
Total Outstanding Dues of Micro Enterprises and Small Enterprises	493.64	586.77
Total Outstanding Dues of Creditors other than Micro Enterprises and Small Enterprises	1,843.03	836.33
(iii) Other Financial Liabilities	219.57	213.62
(b) Other Current Liabilities	551.57	358.04
(c) Provisions	308.51	345.46
Total	36,939.39	39,150.08

Place: Indore
Date: 11/11/2024

For, Syncom Formulations (India) Limited

Kedarmal Shankarlal Bankda
Chairman & Wholetime Director
DIN: 00023050

**SYNCOM FORMULATIONS (INDIA) LIMITED**

Regd. Off :- 7, Niraj Industrial Estate, Off Mahakali Caves Road, Andheri (E) Mumbai-400093

Works - 256-257, Sector - 1, Pitampur, Dist. Dhar-454775

E Mail - finance@sfl.in, Website - www.sfl.in, CIN :- L24239MH1998PLC047759

Standalone Cash Flow Statement for the half year ended 30/09/2024

Particulars	30-09-2024	31-03-2024
	Rs. in Lacs	Audited
Cash Flow from Operating Activities		
Profit before extraordinary item and tax	2,474.81	3,178.39
Adjustments for:	-	-
Gain on Sale of Machinery / (Loss on Sale of Vehicle)	(0.24)	(2.39)
Gain/(Loss) on Actuarial valuation of employee benefits	(9.24)	(18.50)
Depreciation	260.00	472.23
Depreciation Written Back	-	(1.74)
Finance Costs	54.87	444.87
Other Income	(636.91)	(1,221.35)
Operating Profit before working capital changes	2,143.29	2,851.51
Changes in Working Capital		
Inventory	(2,397.16)	(30.76)
Trade Receivables	658.70	(1,807.63)
Loans & Advances	(113.26)	(151.33)
Other Current Assets	(219.27)	(128.37)
Trade Payables	913.57	(617.75)
Other Financial Liabilities	5.95	11.44
Other Current Liabilities	193.53	(47.21)
Short Term Provisions	(36.95)	84.59
Changes in Working Capital	(994.89)	(2,687.02)
Cash Generated from Operations before Tax	1,148.40	164.49
Less: Income Tax Paid	592.32	758.25
Net Cash From Operating Activities	556.08	(593.76)
Cash Flow from Investing Activities		
Change in Property Plant and Equipment, Intangible Assets and Capital Work in Progress	(164.40)	(813.64)
Change in Investment Property	-	-
Change in Fixed Deposit & Accrued Interest	(144.08)	7,313.19
Change in Deposits	(4.95)	(2.15)
Change in Other Non Current Assets	(29.00)	155.58
Change in Trade & Other Deposits	(79.08)	17.46
Other Income	636.91	1,221.35
Change in Investment	(1,272.16)	491.17
Net Cash from Investing Activities	(1,056.76)	8,382.96
Cash Flow from Financing Activities		
Finance Costs	(54.87)	(444.87)
Change in Long Term Liabilities	40.06	61.14
Issue of Warrants & Share capital	-	-
Dividend Paid	-	-
Borrowings	(5,797.82)	(1,153.12)
Net Cash from Financing Activities	(5,812.63)	(1,536.85)
Net Decrease in Cash & Cash Equivalents	(6,313.32)	6,252.35
Cash & Cash Equivalents at the beginning of the Period	6,335.05	82.70
Cash & Cash Equivalents at the End of Period	21.73	6,335.05

Place: Indore
Date: 11/11/2024

For, Syncom Formulations (India) Limited

Kedarmal Shankarlal Bankda
Chairman & Wholetime Director
DIN: 00023050

Limited Review Report on Un-audited Standalone Financial Results for the Quarter & Half Year ended 30th September, 2024 pursuant to Regulation 33 of the SEBI (LODR) Regulations, 2015

To,
The Board of Directors
SYNCOM FORMULATIONS (INDIA) LIMITED
Indore (M.P.)

We have reviewed the accompanying statement of Standalone Unaudited Financial Results of **SYNCOM FORMULATIONS (INDIA) LIMITED ("the Company")**, for the period ended September, 30, 2024 ("the Statement"), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (LODR) Regulations, 2015, as amended including relevant circular issued by the SEBI from time to time.

This statement which is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 Interim Financial Reporting ("IND AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other Accounting principles generally accepted in India and in compliance with the Regulation 33 of the SEBI (LODR) Regulations, 2015, as amended, including relevant circulars issued by the SEBI from time to time. Our responsibility is to issue a report on these Financial Statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "*Review of Interim Financial Information performed by the Independent Auditor of the Entity*", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable Accounting Standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For, Sanjay Mehta & Associates
Chartered Accountants
FRN: 011524C


CA Manish Mittal
(Partner)
M. No. 079452
UDIN: 24079452BJZZEQ9853



Place: Indore
Date: 11th November 2024



SYNCOM FORMULATIONS (INDIA) LIMITED

Regd. Off :- 7, Niraj Industrial Estate, Off Mahakali Caves Road, Andheri (E) Mumbai-400093

Works - 256-257, Sector - 1, Pithampur, Dist: Dhar-464775

E Mail:- finance@sfil.in, Website:- www.sfil.in, CIN :- L24239MH1988PLC047759

CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 30TH SEPTEMBER, 2024

(Rs.In Lakhs) (Except EPS)

S. No.	Particulars	Quarter Ended			Year to date Ended		Year Ended
		30-09-2024	30-06-2024	30-09-2023	30-09-2024	30-09-2023	31-03-2024
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Revenue from Operations	10231.42	8628.88	6383.89	18860.30	12367.47	28338.71
2	Other Income	414.92	230.50	399.74	645.42	587.21	1352.59
3	Total Income (1 + 2)	10646.34	8859.38	6783.63	19505.72	12954.68	27691.30
4	EXPENSES						
	(a) Cost of materials consumed	6857.57	5303.13	3325.08	12160.70	5590.39	13152.91
	(b) Purchases of Stock-in-Trade	1266.24	428.61	837.11	1694.85	1758.53	2710.59
	(c) Changes in inventories of finished goods, Stock-in- Trade and work-in-progress	(1543.72)	(280.40)	(251.75)	(1824.12)	118.47	(175.46)
	(d) Employee benefits expense	1240.39	1084.76	900.10	2325.15	1662.91	3505.77
	(e) Finance costs	15.96	39.03	107.57	54.99	219.74	447.41
	(f) Depreciation and amortization expense	130.00	130.00	87.88	260.00	197.88	472.23
	(g) Other expenses	1194.83	1144.04	932.73	2338.87	1952.58	4190.16
	Total expenses (4)	9161.27	7849.17	5938.72	17010.44	11498.50	24293.61
5	Profit/(loss) before exceptional items and tax (3- 4)	1485.07	1010.21	844.91	2495.28	1456.18	3397.69
6	Exceptional Items	0.00	0.00	0.00	(0.24)	0.00	(2.39)
7	Profit/(loss) before tax (5 - 6)	1485.07	1010.21	844.91	2495.04	1456.18	3395.30
8	Tax expense:						
	(1) Current tax	352.92	243.90	148.62	596.82	324.07	808.45
	(2) Deferred tax	21.33	3.06	45.12	24.39	41.31	55.43
9	Profit (Loss) for the period from continuing operations (7-8)	1110.82	763.25	651.17	1873.83	1090.80	2531.42
10	Profit/(loss) from discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
11	Tax expense of discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
12	Profit/(loss) from Discontinued operations (after tax) (10-11)	0.00	0.00	0.00	0.00	0.00	0.00
13	Profit/(loss) for the period (9 + 12)	1110.82	763.25	651.17	1873.83	1090.80	2531.42
14	Other Comprehensive Income						
	A(i) Items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
	(ii) Income tax relating to items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
	B (i) Items that will be reclassified to profit or loss	391.88	275.93	124.34	667.81	331.11	681.39
	(ii) Income tax relating to items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
15	Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit (Loss) and Other Comprehensive Income for the period)	1502.70	1039.18	775.51	2541.64	1421.91	3212.81
16	Paid up Share Capital of the Company (Face Value 1/-)	9400.00	9400.00	9400.00	9400.00	9400.00	9400.00
17	Reserves excluding revaluation reserves	-	-	-	-	-	19414.28
18	Earnings per equity share (for continuing operation):						
	(1) Basic	0.16	0.11	0.08	0.27	0.15	0.34
	(2) Diluted	0.16	0.11	0.08	0.27	0.15	0.34
19	Earnings per equity share (for discontinued operation):						
	(1) Basic	0.00	0.00	0.00	0.00	0.00	0.00
	(2) Diluted	0.00	0.00	0.00	0.00	0.00	0.00
20	Earnings per equity share (for discontinued & continuing operations)						
	(1) Basic	0.16	0.11	0.08	0.27	0.15	0.34
	(2) Diluted	0.16	0.11	0.08	0.27	0.15	0.34

Place: Indore
Date: 11/11/2024

For, Syncom Formulations (India) Limited

Kedarmal Shankarlal Bankda
Chairman & Wholetime Director
DIN: 00023050



SYNCOM FORMULATIONS (INDIA) LIMITED

Regd. Off :- 7, Niraj Industrial Estate, Off Mahakali Caves Road, Andheri (E) Mumbai-400093

Works :- 256-257, Sector - 1, Pithampur, Dist: Dhar-454775

E Mail :- finance@sfil.in, Website :- www.sfil.in, CIN :- L24239MH1988PLC047759

CONSOLIDATED STATEMENT OF SEGMENT WISE REVENUE, RESULTS ALONG WITH QUARTERLY AND YEARLY UNAUDITED RESULTS

		(Rs.In Lakhs) (Except EPS)					
S. No.	Particulars	Quarter Ended			Year to date Ended		Previous Year Ended
		30-09-2024	30-06-2024	30-09-2023	30-09-2024	30-09-2023	31-03-2024
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Segment Revenue						
	a) Pharmaceuticals Drugs & Formulations	10298.07	8630.31	6401.08	18928.38	12007.87	26,218.06
	b) Trading of Commodities	251.10	132.41	286.04	383.51	743.02	1,071.34
	c) Renting of Property	97.17	96.66	96.51	193.83	203.99	401.89
	Total Segment Revenue	10646.34	8859.38	6783.63	19505.72	12954.68	27,691.29
	Less: Inter Segment Revenue	0.00	0.00	0.00	0.00	0.00	-
	Revenue from Operations	10646.34	8859.38	6783.63	19505.72	12954.68	27,691.29
2	Segment Results Profit(+)/Loss(-) before tax and interest from each segment						
	a) Pharmaceuticals Drugs & Formulations	1403.29	956.25	855.13	2359.54	1481.34	3,454.60
	b) Trading of Commodities	8.40	4.39	5.38	12.79	-0.32	18.49
	c) Renting of Property	89.11	88.59	91.97	177.70	194.90	369.62
	Total Profit before tax	1500.80	1049.23	952.48	2550.03	1675.92	3,842.71
	Less: i) Interest	15.96	39.03	107.57	54.99	219.74	447.41
	ii) Other Un-allocable Expenditure	0.00	0.00	0.00	0.00	0.00	-
	Profit before tax	1484.84	1010.20	844.91	2495.04	1456.18	3,395.30
3	(Segment Asset-Segment Liabilities)						
	Segment Asset						
	a) Pharmaceuticals Drugs & Formulations	31539.20	29849.25	34572.02	31539.20	34572.02	34,706.49
	b) Trading of Commodities	971.86	964.42	1063.79	971.86	1063.79	1,026.45
	c) Renting of Property	4733.45	4733.45	4733.45	4733.45	4733.45	4,733.45
	Total Segment Asset	37244.51	35547.12	40369.26	37,244.51	40,369.26	40,466.39
	Un-allocable Assets	0.00	0.00	0.00	0.00	0.00	0.00
	Net Segment Asset	37244.51	35547.12	40369.26	37,244.51	40,369.26	40,466.39
	Segment Liabilities						
	a) Pharmaceuticals Drugs & Formulations	5552.20	5241.86	13057.38	5552.20	13057.38	11,328.58
	b) Trading of Commodities	243.87	167.45	131.38	243.87	131.38	151.93
	c) Renting of Property	92.52	181.32	163.44	92.52	163.44	171.60
	Total Segment Liabilities	5888.59	5590.63	13352.20	5888.59	13352.20	11,652.11
	Un-allocable Liabilities	0.00	0.00	0.00	0.00	0.00	0.00
	Net Segment Liabilities	5888.59	5590.63	13352.20	5,888.59	13,352.20	11,652.11

Notes:-

- The above results were reviewed by the Audit Committee and approved by the Board at its meeting held on 11/11/2024.
- These above results have been prepared in compliance with the Indian Accounting Standard (referred to as "Ind AS") as notified prescribed under Section 133 of the Companies Act, 2013 read with Companies (Indian Accounting Standards) Rules 2015 as amended from time to time.
- The company is operating in 3 segments i.e. (a) Pharmaceuticals Drugs & Formulations (b) Trading of Commodities (c) Renting of Property, particulars of segment wise results are given as required.
- The Consolidated Statement of Assets and Liabilities as at 30th September, 2024 and the Standalone and Consolidated Statement of Cash Flow is provided as an annexure to this statement.
- Previous period figures have been regrouped/reclassified wherever necessary to confirm to this period classification.
- As required under Regulation 33 of SEBI (LODR) Regulations, 2015 the limited review by the Statutory Auditors have been completed for the quarter ended on 30th September, 2024. The report does not have any impact on the above results and notes which needs explanation.

For, Syncom Formulations (India) Limited

Place: Indore

Date: 11/11/2024


Kedarmal Shankarlal Bankda
 Chairman & Wholetime Director
 DIN: 00023050

**SYNCOM FORMULATIONS (INDIA) LIMITED**Regd. Off :- 7, Niraj Industrial Estate, Off Mahakal Caves Road, Andheri (E) Mumbai-400093
Works - 256-257, Sector - 1, Pithampur, Dist. Dhar-454775

E Mail - finance@sfil.in, Website - www.sfil.in, CIN :- L24239MH1999PLC047759

Consolidated Statement of Assets & Liabilities as at 30/09/2024

Particulars	Rs. In Lacs	30-09-2024 unaudited	31-03-2024 Audited
ASSETS			
Non-current assets			
(a) Property, Plant and Equipment		6,999.22	7,230.60
(b) Capital Work in Progress		142.11	-
(c) Intangible assets		4.72	11.05
(d) Investment Property		4,733.44	4,733.44
(e) Financial Assets		-	-
(i) Investments		555.69	248.92
(ii) Fixed Deposits & Accrued Interest		120.80	691.67
(iii) Deposits		56.85	51.90
(f) Other Non Current Assets		49.56	20.56
Current assets			
(a) Inventories		4,505.31	2,108.15
(b) Financial Assets		-	-
(i) Investments		8,012.38	6,369.94
(ii) Trade Receivables		8,824.32	10,329.84
(iii) Cash And Cash Equivalents		25.02	6,338.34
(iv) Bank Balances other than (iii) above		1,163.16	448.21
(v) Deposits		340.14	412.00
(vi) Loans & Advances		542.63	427.78
(d) Other Current Assets		1,169.16	1,043.99
Total		37,244.51	40,466.39
EQUITY AND LIABILITIES			
Equity			
(a) Equity Share Capital		9,400.00	9,400.00
(b) Other Equity		21,955.91	19,414.28
Liabilities			
Non Current Liabilities			
(a) Financial Liabilities		-	-
(i) Trade and other Deposits		92.52	171.60
(b) Provisions		370.44	330.38
(c) Deferred Tax Liabilities (Net)		522.06	497.67
Current liabilities			
(a) Financial liabilities		-	-
(i) Borrowings		1,424.60	7,248.66
(ii) Trade Payables		-	-
Total Outstanding Dues of Micro Enterprises and Small Enterprises		493.64	594.34
Total Outstanding Dues of Creditors other than Micro Enterprises and Small Enterprises		1,844.07	1,820.05
(iii) Other Financial Liabilities		219.57	213.62
(b) Other Current Liabilities		622.36	412.70
(c) Provisions		299.34	363.09
Total		37,244.51	40,466.39

Place: Indore

Date: 11/11/2024

For, Syncom Formulations (India) Limited

Kedarmal Shankarlal Bankda
Chairman & Wholetime Director
DIN: 00023050

**SYNCOM FORMULATIONS (INDIA) LIMITED**

Regd. Off - 7, Niraj Industrial Estate, Off Mahakali Caves Road, Andheri (E) Mumbai-400093

Works - 256-257, Sector - 1, Pithampur, Dist Dhar-454775


E Mail - finance@sfil.in, Website - www.sfil.in, CIN - L24239MH1998PLC047759

Consolidated Cash Flow Statement for the half year ended 30/09/2024

Particulars	Rs. in Lacs	
	30-09-2024 unaudited	31-03-2024 Audited
Cash Flow from Operating Activities		
Profit before extraordinary item and tax	2,495.28	3,397.69
Adjustments for:	-	-
Gain on Sale of Machinery / (Loss on Sale of Vehicle)	(0.24)	(2.39)
Gain/(Loss) on Actuarial valuation of employee benefits	(9.24)	-
Depreciation	260.00	472.23
Depreciation Written Back	-	(1.74)
Finance Costs	54.99	447.41
Other Income	(636.01)	(1,263.89)
Operating Profit before working capital changes	2,164.78	3,049.32
Changes in Working Capital		
Inventory	(2,397.16)	11.88
Trade Receivables	1,505.52	(2,779.13)
Loans & Advances	(114.85)	(151.21)
Other Current Assets	(53.31)	(324.23)
Trade Payables	(76.68)	369.70
Other Financial Liabilities	5.95	11.44
Other Current Liabilities	209.66	(76.33)
Short Term Provisions	(63.75)	101.18
Changes in Working Capital	(984.62)	(2,836.70)
Cash Generated from Operations before Tax	1,180.16	212.62
Less: Income Tax Paid	596.82	808.45
Net Cash From Operating Activities	583.34	(595.83)
Cash Flow from Investing Activities		
Change in Property Plant and Equipment, Intangible Assets and Capital Work in Progress	(164.40)	(813.64)
Change in Investment Property	-	-
Change in Fixed Deposit & Accrued Interest	(144.08)	7,208.16
Change in Deposits	(4.95)	(2.15)
Change in Other Non Current Assets	(29.00)	155.58
Change in Trade & Other Deposits	(79.08)	17.46
Other Income	636.01	1,263.88
Change in Investment	(1,272.16)	472.67
Net Cash from Investing Activities	(1,057.66)	8,301.96
Cash Flow from Financing Activities		
Finance Costs	(54.99)	(447.41)
Change in Long Term Liabilities	40.06	61.14
Issue of Warrants & Share capital	-	-
Dividend Paid	-	-
Borrowings	(5,824.06)	(1,069.49)
Net Cash from Financing Activities	(5,838.99)	(1,455.76)
Net Decrease in Cash & Cash Equivalents	(6,313.31)	6,250.37
Cash & Cash Equivalents at the beginning of the Period	6,338.34	87.97
Cash & Cash Equivalents at the End of Period	25.03	6,338.34

Place: Indore
Date: 11/11/2024

For, Syncom Formulations (India) Limited


Kedarmal Shankarlal Bankda
Chairman & Wholtime Director
DIN: 00023050

Limited Review Report on Un-audited Consolidated Financial Results for the Quarter and Half Year ended 30th September, 2024 pursuant to Regulation 33 of the SEBI (LODR) Regulations, 2015

To,
The Board of Directors
SYNCOM FORMULATIONS (INDIA) LIMITED
Indore (M.P.)

1. We have reviewed the accompanying statement of Consolidated Unaudited Financial Results of **SYNCOM FORMULATIONS (INDIA) LIMITED** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the period ended September 30, 2024 ("the Statement"), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (LODR) Regulations, 2015, as amended including relevant circular issued by the SEBI from time to time.
2. This statement which is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 Interim Financial Reporting ("IND AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other Accounting principles generally accepted in India and in compliance with the Regulation 33 of the SEBI (LODR) Regulations, 2015, as amended, including relevant circulars issued by the SEBI from time to time. Our responsibility is to issue a report on these Financial Statements based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "*Review of Interim Financial Information performed by the Independent Auditor of the Entity*", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. The Statement includes the results of the following entity:

S. No.	Name of the Company	Relationship with the Holding Company
1.	Sante Biotech Pvt. Ltd.	Wholly Owned Subsidiary
2.	Synmex Pharma Pvt. Ltd.	Wholly Owned Subsidiary
3.	Vincit Biotech International Pvt. Ltd.	Wholly Owned Subsidiary



5. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable Accounting Standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Indore
Date: 11th November 2024

For, Sanjay Mehta & Associates
Chartered Accountants
FRN: 011524C

CA Manish Mittal
(Partner)
M. No. 079452
UDIN: 24079452BJZZER1565

